Cardiac safety is the #1 reason for drug development failure & post-market recalls.
High-quality data and reporting are essential to drive decisions during the entire study cycle from Phase I to Phase IV. As the most trusted name in cardiac safety with 50 years of experience, Clario uses a centralized approach to collection and our data tools are rigorous, responsive, and reliable.
Our goal is always to
- Improve patient safety and enrollment
- Increase data access leading to reduced timelines
- Deliver scientific-grade data to reduce variability
- Solutions with the patients in mind
Regardless of therapeutic area, Clario has mastered collecting reliable evidence needed to bring new drugs and therapies to market. Learn how our solutions and scientific expertise can help you effectively plan, expertly design, efficiently implement and successfully deliver the cardiac safety data for your submission.
Available solutions
Phase 1/ TQT Cardiac Assessment
Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial by collaborating with our Phase 1 Center of Excellence.
ECG – Phase I – IV
Monitor every heartbeat with precision and ensure safety throughout your entire clinical trial.
Arrhythmia
Collect reliable arrhythmia data either in clinic or at home with Clario’s flexible technology solutions.
Blood Pressure Services
Collect accurate, reliable blood
pressure data with consistent devices
and centralized data analysis.
Regulatory Consultation and Statistical Analysis Services
Leverage our industry key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.
Proven results earn trust
13,887
Trials supported
580
New drug approvals
50
Years science
600+
QT studies
200+
Combined years of clinical experience
480+
Unique programs
87+
Approvals from TQTS alone
230+
Sponsors
Cardiac Safety Science Team
Robert Kleiman, MD
VP, Cardiology & Chief Medical Officer
Todd Rudo, MD
VP, Cardiology & Deputy Chief Medical Officer
Borje Darpo, MD, PhD
Chief Scientific Advisor
Joel Morganroth, MD
Chief Scientific Advisor
Mori J. Krantz, MD, FACP, FACC
Chief Science Advisor, Cardiovascular Imaging, Senior Cardiologist, Global Cardiac Safety
Bruce Lloyd, MD
Medical Director
Onglee Weng, MBA, MD
Director, Medical & Scientific Affairs
Jean T. Barbey, MD
Expert Cardiac Safety Medical Advisor
Jeff Heilbraun, MS
VP Medical Affairs, Cardiac Safety
Luc Dekie, PhD
Director, Scientific Affairs
Increase confidence in site performance with Clario Certified Sites.
Clario Certified Sites have completed our Certified Site program to ensure that each study is conducted in an optimal manner and results in the highest quality data. The certification program requires each site to go through an extensive training and testing process. These sites help sponsors reduce study start-up time with well-trained and well-equipped sites.
Learn more or speak with one of our experts
Our team of clinical trial cardiac safety experts are always available to address questions about our cardiac safety solutions. Submit your contact information and we’ll be in touch shortly.